FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285286529> ?p ?o ?g. }

• W4285286529 endingPage "117957352211096" @default.
• W4285286529 startingPage "117957352211096" @default.
• W4285286529 abstract "BACKGROUND There is currently limited literature addressing the reporting of alopecia in multiple sclerosis (MS) patients treated with disease-modifying therapies (DMTs). Anecdotal reports of hair thinning from patients on various DMTs prompted further investigation of a large database. OBJECTIVE To analyze total reports, source of reporting, age distribution, and sex distribution of alopecia associated with DMTs. METHODS FDA Adverse Event Reporting System (FAERS) public dashboard and OpenFDA database were analyzed for alopecia reports between January 1, 2009, and June 30, 2020, attributed to usage in MS of FDA approved DMTs. The main outcomes included total reports for each drug, age, sex distribution, and reporting source. OpenFDA data was used for statistical analyses including reporting odds ratios (ROR) and information components. RESULTS 8759 alopecia reports were identified among 44 114 adverse events in skin and subcutaneous tissue disorders (19.9%). 3701 (42.3%) with teriflunomide, 1675 (19.1%) with dimethyl fumarate, 985 (11.2%) with natalizumab, 926 (10.6%) with fingolimod, 659 (7.5%) with interferon beta-1a, 257 (2.9%) with glatiramer acetate, 243 (2.8%) with ocrelizumab, 124 (1.4%) with interferon beta-1b, 117 (1.3%) with alemtuzumab, 36 (.4%) with siponimod, 24 (.3%) with cladribine, and 12 (.1%) with rituximab. Reports were mostly made by patients (78.3%) and highest in fifth and sixth decades of life. OpenFDA analyses showed increased ROR (ROR 95% confidence interval) of alopecia in females with teriflunomide (18.00, 17.12-18.93), alemtuzumab (1.43, 1.16-1.76), dimethyl fumarate (1.26, 1.18-1.34), and ocrelizumab (1.28, 1.11-1.49). Increased ROR in males was associated with teriflunomide (24.65, 20.72-29.31). CONCLUSION We identified many reports of alopecia for DMTs in addition to teriflunomide. Within the limitations of the database, increased RORs of alopecia were observed for females treated with alemtuzumab, dimethyl fumarate, and ocrelizumab. The source of reporting was largely driven by female patients. Possible alopecia, even if transient, should be considered during patient education when starting DMTs." @default.
• W4285286529 created "2022-07-14" @default.
• W4285286529 creator A5004669262 @default.
• W4285286529 creator A5025601552 @default.
• W4285286529 creator A5054571445 @default.
• W4285286529 creator A5073533913 @default.
• W4285286529 date "2022-01-01" @default.
• W4285286529 modified "2023-09-28" @default.
• W4285286529 title "Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies" @default.
• W4285286529 cites W167367971 @default.
• W4285286529 cites W1960952513 @default.
• W4285286529 cites W1978094617 @default.
• W4285286529 cites W1978971614 @default.
• W4285286529 cites W1986991730 @default.
• W4285286529 cites W1988975677 @default.
• W4285286529 cites W1991197412 @default.
• W4285286529 cites W1991258355 @default.
• W4285286529 cites W1997665745 @default.
• W4285286529 cites W2005475150 @default.
• W4285286529 cites W2017391651 @default.
• W4285286529 cites W2037548712 @default.
• W4285286529 cites W2038316210 @default.
• W4285286529 cites W2049952530 @default.
• W4285286529 cites W2074289946 @default.
• W4285286529 cites W2075881045 @default.
• W4285286529 cites W2091766197 @default.
• W4285286529 cites W2092814331 @default.
• W4285286529 cites W2104948944 @default.
• W4285286529 cites W2116539840 @default.
• W4285286529 cites W2118735809 @default.
• W4285286529 cites W2130008458 @default.
• W4285286529 cites W2139204856 @default.
• W4285286529 cites W2153518194 @default.
• W4285286529 cites W2160866535 @default.
• W4285286529 cites W2169306631 @default.
• W4285286529 cites W2237731314 @default.
• W4285286529 cites W2272606123 @default.
• W4285286529 cites W2282302957 @default.
• W4285286529 cites W2297872050 @default.
• W4285286529 cites W2300679492 @default.
• W4285286529 cites W2322876989 @default.
• W4285286529 cites W2413919393 @default.
• W4285286529 cites W2528133635 @default.
• W4285286529 cites W2591217482 @default.
• W4285286529 cites W2765216118 @default.
• W4285286529 cites W2771598770 @default.
• W4285286529 cites W2790816436 @default.
• W4285286529 cites W2886412054 @default.
• W4285286529 cites W2889708947 @default.
• W4285286529 cites W2892480054 @default.
• W4285286529 cites W2903114461 @default.
• W4285286529 cites W2939130049 @default.
• W4285286529 cites W2969320113 @default.
• W4285286529 cites W2969631385 @default.
• W4285286529 cites W2969862999 @default.
• W4285286529 cites W2992093369 @default.
• W4285286529 cites W3023274850 @default.
• W4285286529 cites W3047562657 @default.
• W4285286529 cites W3113553077 @default.
• W4285286529 cites W3163303553 @default.
• W4285286529 cites W3179262382 @default.
• W4285286529 cites W3199141582 @default.
• W4285286529 cites W4246182889 @default.
• W4285286529 cites W4252639669 @default.
• W4285286529 cites W4299884002 @default.
• W4285286529 doi "https://doi.org/10.1177/11795735221109674" @default.
• W4285286529 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35769950" @default.
• W4285286529 hasPublicationYear "2022" @default.
• W4285286529 type Work @default.
• W4285286529 citedByCount "2" @default.
• W4285286529 countsByYear W42852865292023 @default.
• W4285286529 crossrefType "journal-article" @default.
• W4285286529 hasAuthorship W4285286529A5004669262 @default.
• W4285286529 hasAuthorship W4285286529A5025601552 @default.
• W4285286529 hasAuthorship W4285286529A5054571445 @default.
• W4285286529 hasAuthorship W4285286529A5073533913 @default.
• W4285286529 hasBestOaLocation W42852865291 @default.
• W4285286529 hasConcept C126322002 @default.
• W4285286529 hasConcept C156957248 @default.
• W4285286529 hasConcept C16005928 @default.
• W4285286529 hasConcept C197934379 @default.
• W4285286529 hasConcept C203014093 @default.
• W4285286529 hasConcept C2776036978 @default.
• W4285286529 hasConcept C2777105317 @default.
• W4285286529 hasConcept C2777703276 @default.
• W4285286529 hasConcept C2778577042 @default.
• W4285286529 hasConcept C2778843634 @default.
• W4285286529 hasConcept C2779015954 @default.
• W4285286529 hasConcept C2779134260 @default.
• W4285286529 hasConcept C2779338263 @default.
• W4285286529 hasConcept C2779719350 @default.
• W4285286529 hasConcept C2780640218 @default.
• W4285286529 hasConcept C2780653079 @default.
• W4285286529 hasConcept C2781004633 @default.
• W4285286529 hasConcept C2909675724 @default.
• W4285286529 hasConcept C2911091166 @default.
• W4285286529 hasConcept C71924100 @default.
• W4285286529 hasConceptScore W4285286529C126322002 @default.

• next